{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:46:14Z","timestamp":1777927574644,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>We describe a case of a person living with HIV (PWH) with concurrent use of bictegravir and oxcarbazepine. Concomitant use of these pharmacotherapy regimens is considered contraindicated. A review of the literature, therapeutic bictegravir drug concentration monitoring and viral load evaluations allowed the continued current pharmacotherapy prescription of these medications.<\/jats:p>","DOI":"10.1177\/09564624251335146","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T22:42:34Z","timestamp":1744756954000},"page":"664-666","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bictegravir-emtrictabine-tenofovir alafenamide in combination with oxcarbazepine in a person living with HIV and viral load suppression"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6124-7205","authenticated-orcid":false,"given":"Patricia","family":"Pecora Fulco","sequence":"first","affiliation":[{"name":"Department of Internal Medicine\/Division of Infectious Diseases\/Department of Pharmacy, Virginia Commonwealth University Health, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Gray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Virginia Commonwealth University Health, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_3_3_3_2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv (Accessed January 21, 2025)."},{"key":"e_1_3_3_4_2","unstructured":"University of Liverpool. HIV-drug interaction checker. Available at: https:\/\/hiv-druginteractions.org\/ (Accessed January 21 2025)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03858.x"},{"key":"e_1_3_3_6_2","unstructured":"Novartis Pharmaceuticals Corporation. Trileptal (oxcarbazepine package insert) 2024."},{"key":"e_1_3_3_7_2","volume-title":"Biktarvy (package insert)","author":"Gilead Sciences","year":"2024","unstructured":"Gilead Sciences. Biktarvy (package insert). Foster City, CA: Gilead Sciences, 2024."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199904000-00007"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417751961"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000715"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e1821b42d1"},{"key":"e_1_3_3_12_2","unstructured":"Mpofu R Chandiwana N Sokhela S et al. TAF achieves adequate intracellular tenofovir-DP concentrations with rifampicin based TB therapy. In: Conference on Retroviruses and Opportunistic Infections 2025. March 8-12 2025 San Francisco CA."},{"key":"e_1_3_3_13_2","unstructured":"Osuala EC Nkuhairwe IN Letsoalo MP et al. Pharmacokinetics of twice-daily TAF in adults with HIV-associated TB on BID\/FTC\/TAF and rifampicin. In: Conference on Retroviruses and Opportunistic Infections 2025. March 8-12 2025 San Francisco CA."},{"key":"e_1_3_3_14_2","unstructured":"Naidoo A Naidoo K Letsoalo MP et al. Effacacy safety and PK of BIC\/FTC\/TAF in adults with HIV and tuberculosis on rifampicin at week 24. In: Conference on Retroviruses and Opportunistic Infections 2024. March 3-6 2024. Denver CO USA."}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251335146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624251335146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251335146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:46:34Z","timestamp":1777675594000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624251335146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/09564624251335146"],"URL":"https:\/\/doi.org\/10.1177\/09564624251335146","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]}}}